Company performance
Current Price
as of Jan 06, 2025$58.97
P/E Ratio
N/A
Market Cap
$3.62B
- GEF
Description
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Metrics
Overview
- HQBoston, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerRYTM
- Price$58.97-1.09%
Trading Information
- Market cap$3.62B
- Float87.33%
- Average Daily Volume (1m)541,534
- Average Daily Volume (3m)543,176
- EPS-$4.34
Company
- Revenue$112.53M
- Rev growth (1yr)47.76%
- Net income-$43.64M
- Gross margin87.97%
- EBITDA margin-130.82%
- EBITDA-$43.50M
- EV$3.16B
- EV/Revenue28.11
- P/EN/A
- P/S32.08
- P/B323.04
Documents
SEC Filings
Earnings Calls
Factset Street Account